Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ. Belani CP, et al. Among authors: nemunaitis jj. Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10. Cancer Biol Ther. 2013. PMID: 23792641 Free PMC article. Clinical Trial.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Smith DA, Conkling P, Richards DA, Nemunaitis JJ, Boyd TE, Mita AC, de La Bourdonnaye G, Wages D, Bexon AS. Smith DA, et al. Among authors: nemunaitis jj. Cancer Immunol Immunother. 2014 Aug;63(8):787-96. doi: 10.1007/s00262-014-1547-6. Epub 2014 Apr 27. Cancer Immunol Immunother. 2014. PMID: 24770667 Free PMC article. Clinical Trial.
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Johnson DH, et al. Among authors: nemunaitis jj. J Clin Oncol. 2004 Jun 1;22(11):2184-91. doi: 10.1200/JCO.2004.11.022. J Clin Oncol. 2004. PMID: 15169807 Corrected and republished. Clinical Trial.
Lung cancer vaccines.
Eager R, Harle L, Nemunaitis JJ. Eager R, et al. Among authors: nemunaitis jj. Curr Gene Ther. 2007 Dec;7(6):469-84. doi: 10.2174/156652307782793504. Curr Gene Ther. 2007. PMID: 18045106 Review.
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, Hart J, Kousba A, Gallegos NS, Anderson G, Charles J, Rogers JM, Senzer NN, Mita AC. Mahalingam D, et al. Among authors: nemunaitis jj. Cancer Chemother Pharmacol. 2014 Dec;74(6):1241-50. doi: 10.1007/s00280-014-2602-x. Epub 2014 Oct 11. Cancer Chemother Pharmacol. 2014. PMID: 25304209 Clinical Trial.
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Barve M, et al. Among authors: nemunaitis jj, nemunaitis j, nemunaitis m. J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462. J Clin Oncol. 2008. PMID: 18802154 Clinical Trial.
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. Hurwitz HI, et al. Among authors: nemunaitis jj. J Clin Oncol. 2015 Dec 1;33(34):4039-47. doi: 10.1200/JCO.2015.61.4578. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351344 Free PMC article. Clinical Trial.
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Burris HA, et al. Among authors: nemunaitis jj. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2. J Clin Oncol. 2017. PMID: 28463630 Clinical Trial.
63 results